GlaxoSmithKline Total Current Liabilities from 2010 to 2025
| GSK Stock | USD 38.36 1.28 3.45% |
Total Current Liabilities | First Reported 1986-06-30 | Previous Quarter 20.3 B | Current Value 21.5 B | Quarterly Volatility 7.4 B |
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as Price To Sales Ratio of 2.12, Dividend Yield of 0.0451 or PTB Ratio of 8.65. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
GlaxoSmithKline | Total Current Liabilities |
Latest GlaxoSmithKline PLC's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of GlaxoSmithKline PLC ADR over the last few years. Total Current Liabilities is an item on GlaxoSmithKline PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of GlaxoSmithKline PLC ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. GlaxoSmithKline PLC's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
GlaxoSmithKline Total Current Liabilities Regression Statistics
| Arithmetic Mean | 18,827,988,125 | |
| Geometric Mean | 15,575,039,432 | |
| Coefficient Of Variation | 35.99 | |
| Mean Deviation | 5,399,366,094 | |
| Median | 22,148,000,000 | |
| Standard Deviation | 6,776,164,908 | |
| Sample Variance | 45916410.9T | |
| Range | 26B | |
| R-Value | 0.81 | |
| Mean Square Error | 17047506.9T | |
| R-Squared | 0.65 | |
| Significance | 0.0002 | |
| Slope | 1,150,551,103 | |
| Total Sum of Squares | 688746162.8T |
GlaxoSmithKline Total Current Liabilities History
About GlaxoSmithKline PLC Financial Statements
GlaxoSmithKline PLC investors utilize fundamental indicators, such as Total Current Liabilities, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 24.2 B | 25.4 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of GlaxoSmithKline PLC Correlation against competitors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.167 | Dividend Share 0.61 | Earnings Share 1.53 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.